Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RTH258 versus aflibercept in neovascular age-related macular degeneration
NL-OMON47226Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Nov 2015
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in exudative macular degeneration comparing RTH258 6 mg with Aflibercept 2 mg (2 arms). Primary endpoint: Change in best-corrected visual acuity from baseline to Week 48. Started Nov 2015; status: active, not recruiting.
02
Drugs
brolucizumabaflibercept
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NL-OMON47226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47226.